Postnatally, GPR37 is expressed in neurons in “Parkinson’s disease-associated” nuclei including the caudate, putamen, and substantia nigra (Donohue et al., 1998; Imai et al., 2007) and modulates dopaminergic neurotransmission, either by changing dopamine levels (Marazziti et al., 2004; Imai et al., 2007), reducing postsynaptic sensitivity of striatal dopamine receptors (Marazziti et al., 2007) and/or inhibiting adenosine A2A receptor cell surface expression and function in the striatum by forming GPR37/A2AR heteromers (Morato et al., 2017). This evidence concerns the gene GPR37 and Parkinson disease.